CompletedNCT04201899HYPO-P-ICUUpdated Feb 2, 2021

HYPOPhosphatemia in the Intensive Care: A One-day Point Prevalence Survey

An observational study in Critically Ill, sponsored by Centre Hospitalier Universitaire Vaudois. Completed at 4 sites in 3 countries. Per ClinicalTrials.gov, last updated 2021-02-02.

Sponsored by Centre Hospitalier Universitaire Vaudois · Observational

Study type: Observational
Model: Cohort
Time perspective: Prospective
Enrollment: 890
Sex: All

Study summary

The point prevalence survey aims at defining the until now unknown real prevalence of hypophosphatemia (defined as blood phosphate value \< 0.8 mmol/l) in international critical care settings

Read the detailed description

The survey will be conducted on one single day in each centre (D-day), within a week defined by the project coordinator (International PI). On D-Day, the local investigators will be asked

to complete questions aiming at describing their ICU (number of beds, number of patients present on D-Day, type medical/surgical/other, local phosphate reference value, presence of an hypophosphatemia treatment protocol in the ICU and route of phosphate delivery in case of hypophosphatemia)
to indicate how many patients had a blood phosphate \<0.08 mmol/l, for each patient with hypophosphatemia, to record the exact lowest value on D-Day, and to record age, number of days in ICU on D-Day, presence (or not) of artificial nutrition and continuous renal replacement therapy, if any phosphate administration is ongoing Data will be recorded in and electronic Case Report Form (e-CRF) in REDCap, and analysed with descriptive statistics No outcome data will be recorded (pure point-prevalence) There is no intervention

Conditions studied

Critically Ill

Browse trials for

Critical Illness 1,780

Keywords

Phosphate

In context

Critical Illness

1,780 studies on the registry are indexed under Critical Illness; 442 are open to participants now.

This study's enrollment of 890 is above the median of 140 across 814 observational studies indexed under Critical Illness.

Browse Critical Illness studies →

Lead sponsor

Centre Hospitalier Universitaire Vaudois is the lead sponsor of 208 studies on the registry; 48 are open to participants now.

Browse Centre Hospitalier Universitaire Vaudois studies →

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

Critically ill patients: adults and children

Eligibility criteria

Inclusion Criteria: blood phosphate value \< 0.8 mmol -

Exclusion Criteria: Blood phosphate value >0.8 mmol/l

Study design

Observational model: Cohort
Time perspective: Prospective
Enrollment: 890 participants (actual)
Target follow-up: 1 Day
Patient registry: Yes

Interventions

Dietary supplementNo intervention - pure observation
Phosphate administration (yes or no)

What researchers measure

Primary outcomes

Prevalence of hypophosphatemia
Blood value \< 0.8 mmol/l
Time frame: 1 day

Study locations

4 sites

Tartu University Hospital
Tartu, 50407, Estonia
Hôpital Pasteur 2
Nice, 06000, France
Lausanne University Hospital
Lausanne, VD 1011, Switzerland
Hôpital de Nyon
Nyon, 1260, Switzerland

References and documents

Publications

Berger MM, Appelberg O, Reintam-Blaser A, Ichai C, Joannes-Boyau O, Casaer M, Schaller SJ, Gunst J, Starkopf J; ESICM-MEN section. Prevalence of hypophosphatemia in the ICU - Results of an international one-day point prevalence survey. Clin Nutr. 2021 May;40(5):3615-3621. doi: 10.1016/j.clnu.2020.12.017. Epub 2020 Dec 29. PubMed 33454128 ↗

Individual participant data

Plan to share: No — Data will be collected in central REDCap database. No individual patient data will be made available

Timeline

Tracking since Sep 25, 2026

ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Jul 2020, 4 months.

Of 439 non-industry observational studies under Critical Illness, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's 4 months is below that.

Counting every sponsor, half of 442 studies reached it within 23 months; a quarter within 12 and three quarters within 46.

Critical Illness covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered: Dec 14, 2019
First posted: Dec 17, 2019
StartActual: Mar 9, 2020
Primary completionActual: Jul 31, 2020
CompletionActual: Jul 31, 2020
Last update: Feb 2, 2021

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

No changes since tracking began. The registry record was last updated on Feb 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT04201899
Lead sponsor: Centre Hospitalier Universitaire Vaudois
Collaborators: European Society of Intensive Care Medicine
Responsible party: Mette M Berger (Principal Investigator, Centre Hospitalier Universitaire Vaudois) — Principal investigator
First posted: Dec 17, 2019
Start date: Mar 9, 2020
Primary completion: Jul 31, 2020
Completion: Jul 31, 2020
Last update: Feb 2, 2021

Study contacts

Mette M BERGER, MD PhD

principal investigator · Lausanne University Hospital, Lausanne, Switzerland

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Critical Illness →

Other studies from this sponsor

Centre Hospitalier Universitaire Vaudois →

Start the discussion